Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV-52 in mild active Crohn's disease or ulcerative colitis
ACTRN12607000617460Phase 2Completed
- Sponsor
- Kazia Therapeutics
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NV-52 in Crohn's disease and autoimmune colitis, sponsored by Kazia Therapeutics. Primary endpoint: Effect of NV-52 on inflammatory surrogate markers of inflammatory bowel disease. Started Dec 2007; status: completed.
02
Drugs
NV-52
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on ACTRN12607000617460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000617460.